{"gene":"SGCE","run_date":"2026-06-10T07:46:31","timeline":{"discoveries":[{"year":2003,"finding":"The maternal allele of SGCE is methylated while the paternal allele is unmethylated in peripheral blood leukocytes and brain tissue, establishing maternal imprinting of SGCE. Expression from the maternal allele is silenced (weak RT-PCR signal in matUPD7 vs. strong signal in patUPD7 cell lines), confirming that only the paternal allele is expressed.","method":"Bisulfite genomic sequencing of CpG dinucleotides in the promoter/first exon; RT-PCR in uniparental disomy 7 (UPD7) lymphoblastoid cell lines","journal":"European journal of human genetics : EJHG","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct methylation assay with functional expression confirmation, replicated across blood and brain tissue and in UPD7 cell lines","pmids":["12634861"],"is_preprint":false},{"year":2007,"finding":"MDS-associated SGCE missense mutations (H36P, H36R, L172R) cause intracellular retention of ε-sarcoglycan and prevent trafficking to the plasma membrane. The mutant proteins become polyubiquitinated and are rapidly degraded by the proteasome. TorsinA (mutated in DYT1 dystonia) binds to and promotes degradation of misfolded ε-sarcoglycan mutants when co-expressed.","method":"Biosynthesis and trafficking assays in cultured cells; cell-surface expression analysis; co-immunoprecipitation of torsinA with ε-sarcoglycan mutants; proteasome inhibitor experiments; polyubiquitination assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (trafficking assay, co-IP, ubiquitination assay, proteasome inhibition) in a single focused study","pmids":["17200151"],"is_preprint":false},{"year":2010,"finding":"Loss of ε-sarcoglycan (Sgce KO mice) results in significantly decreased striatal dopamine D2 receptor (D2R) protein levels without altering dopamine transporter (DAT) or D1 receptor levels, and leads to increased dopamine release after amphetamine injection, suggesting ε-SG plays a role in regulating D2R expression and striatal dopamine homeostasis.","method":"Western blot for D2R, DAT, D1R in striatum of Sgce KO mice; in vivo microdialysis measuring dopamine release after amphetamine injection","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (Western blot + microdialysis) in single-lab KO mouse study","pmids":["22438980"],"is_preprint":false},{"year":2011,"finding":"ε-Sarcoglycan is required in cerebellar Purkinje cells for motor learning; Purkinje cell-specific Sgce conditional knockout (Sgce pKO) mice show motor learning deficits. Additionally, Sgce KO mice show abnormal nuclear envelope morphology in cerebellar Purkinje cells detected by transmission electron microscopy.","method":"Cerebellar Purkinje cell-specific conditional Sgce knockout mice; beam-walking behavioral tests; transmission electron microscopy of nuclear envelope","journal":"Behavioural brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined behavioral phenotype plus ultrastructural analysis, single lab","pmids":["22040906"],"is_preprint":false},{"year":2010,"finding":"Mice carrying mutations in both Dyt1 (torsinA) and Sgce (ε-sarcoglycan) show earlier onset of motor deficits compared to single mutants, suggesting genetic interaction between these two dystonia genes. Western blot analysis suggested that functional deficits of torsinA and ε-sarcoglycan may independently cause motor deficits rather than acting in a shared pathway.","method":"Double mutant mouse generation; beam-walking test; Western blot with novel monoclonal anti-mouse ε-sarcoglycan antibody developed in Sgce KO mice","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis experiment in double-mutant mice with behavioral readout, single lab","pmids":["20627944"],"is_preprint":false},{"year":2016,"finding":"Loss of Sgce in the striatum specifically impairs long-term depression (LTD) at corticostriatal glutamatergic synapses in medium spiny neurons, without affecting intrinsic electrophysiological properties or basal synaptic transmission. Pharmacological inhibition of adenosine A2A receptors (A2AR) restores LTD in Sgce mutant mice.","method":"RNAseq of Sgce mutant striatum; electrophysiological recordings (LTD induction by high-frequency stimulation) in striatal medium spiny neurons and cholinergic interneurons; pharmacological A2AR inhibition","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro electrophysiology with pharmacological rescue, combined with transcriptomic analysis, multiple orthogonal methods","pmids":["28823931"],"is_preprint":false},{"year":2019,"finding":"Acute knockdown of Sgce specifically in the cerebellum (but not the basal ganglia) of adult mice produces dystonia and repetitive myoclonic-like jerking movements that improve after ethanol administration, demonstrating that cerebellar loss of ε-sarcoglycan is sufficient to cause the core DYT11 motor symptoms and that aberrant cerebellar activity underlies the motor phenotype.","method":"shRNA-mediated acute knockdown of Sgce in adult mouse cerebellum or basal ganglia; behavioral assessment of dystonia and myoclonus; ethanol administration","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — region-specific knockdown with clear positive vs. negative controls (cerebellum vs. basal ganglia), ethanol-reversibility confirms specificity","pmids":["31868164"],"is_preprint":false},{"year":2016,"finding":"Immunoaffinity purification followed by mass spectrometry of Sgce-mutant mouse brain showed significant reductions of ε-SG and other interacting sarcoglycans, indicating that ε-sarcoglycan forms complexes with other sarcoglycan family members in brain. The brain-specific Sgce isoform incorporating exon 11b is most highly expressed in cerebellum (Purkinje cells and dentate nucleus neurons).","method":"Immunoaffinity purification with pan- or brain-specific ε-SG antibodies followed by mass spectrometry; isoform expression analysis; gene-trap mouse model","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry-based interactome in brain tissue, single lab, supported by expression analysis","pmids":["27890709"],"is_preprint":false},{"year":2017,"finding":"iPSC-derived cortical neurons from myoclonus-dystonia patients with SGCE mutations (W100G and R102X) maintain faithful maternal imprinting of SGCE (differential methylation is tissue-independent). The brain-specific SGCE mRNA isoform and ε-sarcoglycan protein are detected in iPSC-derived neurons (but not in fibroblasts), and neuronal protein levels are reduced in both mutant lines.","method":"Methylation-specific PCR; cDNA analysis; RT-PCR for brain-specific isoform; Western blot for ε-sarcoglycan protein; iPSC reprogramming and neuronal differentiation","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (methylation, expression, protein) in patient-derived iPSC-neurons, single lab","pmids":["28155872"],"is_preprint":false},{"year":2020,"finding":"SGCE functions as a sponge molecule that prevents interaction between EGFR and its E3 ubiquitin ligase c-Cbl, thereby inhibiting EGFR lysosomal degradation and stabilizing EGFR protein in breast cancer stem cells. SGCE depletion promotes sensitivity to EGFR tyrosine kinase inhibitors.","method":"Co-immunoprecipitation of SGCE with EGFR and c-Cbl; SGCE knockdown with assessment of EGFR protein stability; in vitro and in vivo functional assays; single-cell resolution gene expression analysis","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional consequence of knockdown, single lab, in cancer cell context distinct from neurological function","pmids":["32714745"],"is_preprint":false},{"year":2023,"finding":"SGCE mutations cause cortical neuronal hyperexcitability: iPSC-derived cortical glutamatergic neurons carrying SGCE mutations show increased network activity, greater propensity for action potential generation, longer axon initial segments, and more complex dendritic morphology compared to isogenic wild-type controls. SGCE mutations are associated with higher presynaptic neurexin-1 and lower postsynaptic neuroligin-4 levels, indicating disruption of synaptic adhesion molecule expression.","method":"CRISPR/Cas9-edited human embryonic stem cell line with SGCE compound heterozygous mutation; patient-derived iPSC lines with isogenic wild-type controls; Ca2+ imaging; microelectrode array; single-cell patch clamp; bulk RNA sequencing; dendritic morphology analysis; Western blot for synaptic proteins and receptor subunits","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (electrophysiology, Ca2+ imaging, MEA, morphology, proteomics) with isogenic controls in two independent cell models","pmids":["36204995"],"is_preprint":false},{"year":2021,"finding":"iPSC-derived striatal medium spiny neurons (MSNs) from SGCE mutation carriers show elevated basal intracellular Ca2+ content, lower frequency of spontaneous Ca2+ signals, increased Ca2+ amplitudes upon glycine and acetylcholine application, reduced GABAergic synaptic density, and elevated amplitudes of miniature postsynaptic currents and action potentials, indicating that SGCE loss causes specific alterations in MSN calcium signaling and synaptic function.","method":"iPSC-derived striatal MSN differentiation; calcium imaging; whole-cell patch-clamp recordings; immunofluorescence for GABAergic synaptic density; pharmacological blocking with verapamil","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple electrophysiological and imaging methods in patient-derived iPSC model, single lab","pmids":["33808167"],"is_preprint":false},{"year":2023,"finding":"SGCE interacts with the transcription factor Sp1 and translocates into the nucleus, leading to increased transcription of the secreted oncoprotein FGF-BP1, which in turn activates FGF-FGFR signaling to promote cancer cell stemness.","method":"Co-immunoprecipitation of SGCE with Sp1; nuclear translocation assay; FGF-BP1 promoter transcription assays; SGCE knockdown with FGF-BP1 expression measurement","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and nuclear localization with functional transcriptional readout, single lab, cancer cell context","pmids":["37838174"],"is_preprint":false},{"year":2022,"finding":"Two SGCE missense mutations (c.662G>T/p.Gly221Val and c.1345A>G/p.Met449Val) and a 15 bp deletion (c.168_182del/p.Phe58_Leu62del) cause significant reduction in cell membrane expression of ε-sarcoglycan. Minigene assays demonstrated that c.662G>T and c.825+1G>C mutations cause complete skipping of exon 5 and exon 6, respectively.","method":"HiBiT bioluminescence assay for cell membrane expression; minigene splicing assay","journal":"Clinical genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — functional cell membrane trafficking assay and minigene splicing assay, two orthogonal methods, single lab","pmids":["36161439"],"is_preprint":false},{"year":2025,"finding":"Purkinje cells from Sgce KO mice show altered spontaneous firing and intrinsic excitability changes compared to wild-type mice, without changes in intrinsic membrane properties. Female Sgce KO mice have more profound alterations in Purkinje cell firing than males, correlating with earlier symptom onset and more pronounced myoclonus in female mice.","method":"Acute cerebellar slice electrophysiological recordings in Sgce KO mice; comparison of spontaneous firing rates and intrinsic excitability between sexes","journal":"Dystonia (Lausanne, Switzerland)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ex vivo electrophysiology in KO mice, single lab, single method but clear functional readout","pmids":["40557327"],"is_preprint":false},{"year":2026,"finding":"SGCE mutation-carrying MGE-derived inhibitory GABAergic neurons show transcriptomic dysregulation in genes related to axonal organization, synaptic signalling, and action potential generation; reduced neurite outgrowth; lower calcium responses to GABA; decreased neuronal excitability and network activity; and fewer spontaneous postsynaptic currents compared to isogenic wild-type controls. This hypoactive inhibitory phenotype contrasts with the hyperexcitable phenotype previously observed in SGCE-mutant cortical glutamatergic neurons, indicating disruption of excitatory-inhibitory balance.","method":"Patient-derived iPSC and CRISPR/Cas9-edited ESC lines; single-cell RNA sequencing; Ca2+ imaging; multi-electrode array; whole-cell patch-clamp; dendritic morphology analysis","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (scRNA-seq, electrophysiology, Ca2+ imaging, MEA, morphology) with isogenic controls, replicates and extends prior cortical neuron findings","pmids":["40711998"],"is_preprint":false}],"current_model":"ε-Sarcoglycan (SGCE) is a maternally imprinted, paternally expressed transmembrane protein whose loss-of-function causes myoclonus-dystonia (DYT11) through disruption of cerebellar Purkinje cell firing and corticostriatal long-term depression, with disease-associated missense mutations causing intracellular retention, polyubiquitination and proteasomal degradation of the misfolded protein; torsinA promotes degradation of these mutants. In cortical glutamatergic neurons, SGCE loss results in hyperexcitability and altered synaptic adhesion molecule expression (higher neurexin-1, lower neuroligin-4), while in striatal GABAergic neurons it causes hypoactivity and reduced synaptic density, collectively disrupting excitatory-inhibitory balance. ε-Sarcoglycan also regulates striatal dopamine D2 receptor expression and dopamine release, and in cancer cells acts as a scaffold that prevents EGFR-c-Cbl interaction to stabilize EGFR and, separately, interacts with Sp1 to promote nuclear transcription of FGF-BP1."},"narrative":{"mechanistic_narrative":"ε-Sarcoglycan (SGCE) is a maternally imprinted, paternally expressed transmembrane sarcoglycan whose loss disrupts neuronal excitability and synaptic function, and whose mutation causes myoclonus-dystonia (DYT11) [PMID:12634861, PMID:31868164]. The maternal allele is silenced by promoter methylation in blood and brain, so disease arises from paternally inherited loss-of-function alleles [PMID:12634861], an imprinting pattern faithfully maintained in patient iPSC-derived neurons that express a brain-specific exon-11b isoform most abundant in cerebellum [PMID:27890709, PMID:28155872]. Disease-associated missense mutations cause intracellular retention, block trafficking to the plasma membrane, and trigger polyubiquitination and proteasomal degradation of the misfolded protein, with torsinA (the DYT1 dystonia protein) binding and promoting degradation of these mutants; other mutations reduce surface expression through exon skipping [PMID:17200151, PMID:36161439]. Functionally, ε-sarcoglycan acts within the cerebellum where its acute loss is sufficient to produce ethanol-responsive dystonia and myoclonus, and where Purkinje cell firing and intrinsic excitability are altered in a sex-dependent manner [PMID:31868164, PMID:40557327]. In the striatum, loss selectively impairs corticostriatal long-term depression in a manner rescuable by adenosine A2A receptor blockade, and reduces dopamine D2 receptor levels while increasing amphetamine-evoked dopamine release [PMID:28823931, PMID:22438980]. Across human neuronal models, SGCE loss disrupts excitatory-inhibitory balance—producing hyperexcitable cortical glutamatergic neurons with altered synaptic adhesion molecules (higher neurexin-1, lower neuroligin-4) but hypoactive GABAergic and striatal neurons with reduced synaptic density [PMID:36204995, PMID:33808167, PMID:40711998]. In cancer cells SGCE has separable roles, acting as a scaffold that blocks EGFR–c-Cbl interaction to stabilize EGFR and interacting with Sp1 to drive nuclear transcription of FGF-BP1 [PMID:32714745, PMID:37838174].","teleology":[{"year":2003,"claim":"Established the genetic basis for parent-of-origin inheritance in DYT11 by showing SGCE is maternally imprinted, explaining why only paternally inherited mutations cause disease.","evidence":"Bisulfite sequencing and RT-PCR in UPD7 lymphoblastoid lines across blood and brain","pmids":["12634861"],"confidence":"High","gaps":["Does not identify the imprinting control mechanism or trans-acting factors","Does not link imprinting to a specific cellular function of the protein"]},{"year":2007,"claim":"Defined the molecular consequence of disease missense mutations—misfolding, ER retention, and proteasomal degradation—and connected SGCE to torsinA, a second dystonia protein.","evidence":"Trafficking, co-IP, ubiquitination, and proteasome inhibition assays in cultured cells","pmids":["17200151"],"confidence":"High","gaps":["Does not establish the normal surface function of wild-type ε-sarcoglycan","torsinA interaction tested only with mutants, not normal turnover"]},{"year":2010,"claim":"Linked ε-sarcoglycan loss to striatal dopamine homeostasis, implicating D2 receptor regulation and dopamine release as candidate disease mechanisms.","evidence":"Western blot and in vivo microdialysis in Sgce KO mice","pmids":["22438980"],"confidence":"Medium","gaps":["Mechanism by which ε-SG regulates D2R levels unknown","Does not connect dopamine changes to motor phenotype"]},{"year":2010,"claim":"Tested whether the two dystonia genes act in a shared pathway, finding a genetic interaction but evidence for independent contributions to motor deficits.","evidence":"Dyt1/Sgce double-mutant mice with beam-walking and Western blot","pmids":["20627944"],"confidence":"Medium","gaps":["Does not resolve whether the interaction is direct or convergent","Mechanism of earlier onset not defined"]},{"year":2011,"claim":"Localized a motor-learning requirement for ε-sarcoglycan to cerebellar Purkinje cells and revealed nuclear envelope abnormalities there.","evidence":"Purkinje cell-specific conditional Sgce KO, beam-walking, and TEM","pmids":["22040906"],"confidence":"Medium","gaps":["Functional significance of nuclear envelope defect unclear","Does not link Purkinje phenotype to myoclonus or dystonia"]},{"year":2016,"claim":"Identified a defined synaptic plasticity defect—impaired corticostriatal LTD—with a pharmacological rescue point at the adenosine A2A receptor.","evidence":"Striatal slice electrophysiology with A2AR inhibition plus RNAseq in Sgce mutant mice","pmids":["28823931"],"confidence":"High","gaps":["Molecular link between ε-SG and A2AR signaling unknown","LTD defect not yet tied to behavioral output"]},{"year":2016,"claim":"Demonstrated that ε-sarcoglycan forms complexes with other sarcoglycans in brain and identified a cerebellum-enriched brain-specific isoform.","evidence":"Immunoaffinity purification–mass spectrometry and isoform analysis in mouse brain","pmids":["27890709"],"confidence":"Medium","gaps":["Functional role of the brain sarcoglycan complex not defined","Identity of all complex members and stoichiometry incomplete"]},{"year":2017,"claim":"Confirmed in human patient iPSC-neurons that SGCE imprinting is tissue-independent and that mutant protein levels are reduced, validating the model in human cells.","evidence":"Methylation PCR, isoform RT-PCR, and Western blot in patient iPSC-derived neurons","pmids":["28155872"],"confidence":"Medium","gaps":["Does not assess neuronal physiology or function","Two mutation lines only"]},{"year":2019,"claim":"Showed that cerebellar loss of ε-sarcoglycan alone is sufficient to produce the core, ethanol-responsive DYT11 motor phenotype, establishing the cerebellum as a primary disease locus.","evidence":"Region-specific shRNA knockdown in adult mouse cerebellum versus basal ganglia with behavioral and ethanol testing","pmids":["31868164"],"confidence":"High","gaps":["Cellular circuit producing aberrant activity not fully mapped","Mechanism of ethanol responsiveness unknown"]},{"year":2021,"claim":"Characterized striatal MSN dysfunction in human cells, revealing altered calcium signaling and reduced GABAergic synaptic density upon SGCE loss.","evidence":"Calcium imaging, patch-clamp, and immunofluorescence in patient iPSC-derived MSNs","pmids":["33808167"],"confidence":"Medium","gaps":["Causal link between Ca2+ alterations and synaptic loss unclear","Single-lab patient lines"]},{"year":2022,"claim":"Extended the trafficking-defect model to additional mutation classes, showing both missense and splice mutations reduce surface ε-sarcoglycan.","evidence":"HiBiT membrane-expression and minigene splicing assays","pmids":["36161439"],"confidence":"Medium","gaps":["Does not assess downstream neuronal consequences","Splicing outcomes inferred from minigene, not patient tissue"]},{"year":2023,"claim":"Demonstrated that SGCE-mutant human cortical glutamatergic neurons are hyperexcitable with altered synaptic adhesion molecule expression, defining a cell-autonomous excitatory phenotype.","evidence":"Ca2+ imaging, MEA, patch-clamp, RNAseq, and morphology in isogenic-controlled iPSC/ESC cortical neurons","pmids":["36204995"],"confidence":"High","gaps":["Mechanism linking ε-SG loss to neurexin-1/neuroligin-4 changes unknown","Does not address inhibitory neuron behavior"]},{"year":2023,"claim":"Revealed a nuclear, transcriptional oncogenic role in which SGCE partners with Sp1 to drive FGF-BP1 expression and cancer stemness.","evidence":"Co-IP with Sp1, nuclear translocation, and promoter transcription assays in cancer cells","pmids":["37838174"],"confidence":"Medium","gaps":["How a transmembrane protein reaches the nucleus is unexplained","Relationship to neuronal function unknown"]},{"year":2025,"claim":"Showed Purkinje cell firing and intrinsic excitability are altered in Sgce KO mice with a sex difference that correlates with disease severity.","evidence":"Ex vivo cerebellar slice electrophysiology comparing sexes in Sgce KO mice","pmids":["40557327"],"confidence":"Medium","gaps":["Molecular basis of sex difference not defined","Single physiological readout"]},{"year":2026,"claim":"Completed the excitatory-inhibitory picture by showing SGCE-mutant inhibitory GABAergic neurons are hypoactive, contrasting with hyperexcitable glutamatergic neurons.","evidence":"scRNA-seq, Ca2+ imaging, MEA, patch-clamp, and morphology in isogenic-controlled iPSC/ESC GABAergic neurons","pmids":["40711998"],"confidence":"High","gaps":["Mechanism producing opposite phenotypes across neuron types unknown","Network-level consequence of imbalance not directly measured"]},{"year":null,"claim":"The normal biochemical function of plasma-membrane ε-sarcoglycan and how its loss mechanistically produces opposite excitability changes in distinct neuron classes remain undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No defined molecular activity for wild-type membrane ε-sarcoglycan","Mechanism connecting sarcoglycan complex to neuronal excitability unknown","Reconciliation of neuronal versus cancer-nuclear roles unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[9]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[10,11]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,13]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[5,6,10,15]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,13]}],"complexes":["sarcoglycan complex"],"partners":["TOR1A","EGFR","CBL","SP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O43556","full_name":"Epsilon-sarcoglycan","aliases":[],"length_aa":437,"mass_kda":49.9,"function":"Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix","subcellular_location":"Cell membrane, sarcolemma; Cytoplasm, cytoskeleton; Cell projection, dendrite; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/O43556/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SGCE","classification":"Not Classified","n_dependent_lines":161,"n_total_lines":1208,"dependency_fraction":0.13327814569536423},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SGCE","total_profiled":1310},"omim":[{"mim_id":"618905","title":"SILVER-RUSSELL SYNDROME 2; SRS2","url":"https://www.omim.org/entry/618905"},{"mim_id":"618859","title":"NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT AUTISTIC FEATURES AND/OR STRUCTURAL BRAIN ABNORMALITIES; NEDASB","url":"https://www.omim.org/entry/618859"},{"mim_id":"609810","title":"PATERNALLY EXPRESSED GENE 10; PEG10","url":"https://www.omim.org/entry/609810"},{"mim_id":"608099","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3","url":"https://www.omim.org/entry/608099"},{"mim_id":"607488","title":"DYSTONIA 15, MYOCLONIC; DYT15","url":"https://www.omim.org/entry/607488"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"ovary","ntpm":115.3}],"url":"https://www.proteinatlas.org/search/SGCE"},"hgnc":{"alias_symbol":[],"prev_symbol":["DYT11"]},"alphafold":{"accession":"O43556","domains":[{"cath_id":"2.60.40.10","chopping":"49-151","consensus_level":"high","plddt":88.2199,"start":49,"end":151},{"cath_id":"-","chopping":"161-278","consensus_level":"high","plddt":88.6276,"start":161,"end":278}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43556","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43556-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43556-F1-predicted_aligned_error_v6.png","plddt_mean":74.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SGCE","jax_strain_url":"https://www.jax.org/strain/search?query=SGCE"},"sequence":{"accession":"O43556","fasta_url":"https://rest.uniprot.org/uniprotkb/O43556.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43556/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43556"}},"corpus_meta":[{"pmid":"12634861","id":"PMC_12634861","title":"The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted.","date":"2003","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/12634861","citation_count":114,"is_preprint":false},{"pmid":"18362280","id":"PMC_18362280","title":"Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations.","date":"2008","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18362280","citation_count":100,"is_preprint":false},{"pmid":"17200151","id":"PMC_17200151","title":"SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17200151","citation_count":96,"is_preprint":false},{"pmid":"23365103","id":"PMC_23365103","title":"SGCE mutations cause psychiatric disorders: clinical and genetic characterization.","date":"2013","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23365103","citation_count":87,"is_preprint":false},{"pmid":"18205193","id":"PMC_18205193","title":"Myoclonus-dystonia: significance of large SGCE deletions.","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18205193","citation_count":84,"is_preprint":false},{"pmid":"12620933","id":"PMC_12620933","title":"Temporal regulation of the expression of syncytin (HERV-W), maternally imprinted PEG10, and SGCE in human placenta.","date":"2003","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/12620933","citation_count":72,"is_preprint":false},{"pmid":"21157498","id":"PMC_21157498","title":"SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis?","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21157498","citation_count":70,"is_preprint":false},{"pmid":"17296918","id":"PMC_17296918","title":"Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers.","date":"2007","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17296918","citation_count":69,"is_preprint":false},{"pmid":"32714745","id":"PMC_32714745","title":"SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR.","date":"2020","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/32714745","citation_count":63,"is_preprint":false},{"pmid":"23284065","id":"PMC_23284065","title":"Metabolic changes in DYT11 myoclonus-dystonia.","date":"2013","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23284065","citation_count":62,"is_preprint":false},{"pmid":"25209853","id":"PMC_25209853","title":"SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype.","date":"2014","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25209853","citation_count":59,"is_preprint":false},{"pmid":"26783545","id":"PMC_26783545","title":"Psychiatric disorders, myoclonus dystonia and SGCE: an international study.","date":"2015","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26783545","citation_count":44,"is_preprint":false},{"pmid":"21386109","id":"PMC_21386109","title":"Impaired saccadic adaptation in DYT11 dystonia.","date":"2011","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21386109","citation_count":43,"is_preprint":false},{"pmid":"18759336","id":"PMC_18759336","title":"A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome.","date":"2008","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/18759336","citation_count":43,"is_preprint":false},{"pmid":"22438980","id":"PMC_22438980","title":"Alteration of striatal dopaminergic neurotransmission in a mouse model of DYT11 myoclonus-dystonia.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22438980","citation_count":39,"is_preprint":false},{"pmid":"31868164","id":"PMC_31868164","title":"Acute cerebellar knockdown of Sgce reproduces salient features of myoclonus-dystonia (DYT11) in mice.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31868164","citation_count":38,"is_preprint":false},{"pmid":"20627944","id":"PMC_20627944","title":"Earlier onset of motor deficits in mice with double mutations in Dyt1 and Sgce.","date":"2010","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20627944","citation_count":36,"is_preprint":false},{"pmid":"19896264","id":"PMC_19896264","title":"Clinical and neurophysiological improvement of SGCE myoclonus-dystonia with GPi deep brain stimulation.","date":"2009","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/19896264","citation_count":36,"is_preprint":false},{"pmid":"28823931","id":"PMC_28823931","title":"Abnormal striatal plasticity in a DYT11/SGCE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28823931","citation_count":35,"is_preprint":false},{"pmid":"22040906","id":"PMC_22040906","title":"Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models.","date":"2011","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22040906","citation_count":34,"is_preprint":false},{"pmid":"27890709","id":"PMC_27890709","title":"Role of major and brain-specific Sgce isoforms in the pathogenesis of myoclonus-dystonia syndrome.","date":"2016","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/27890709","citation_count":31,"is_preprint":false},{"pmid":"23677909","id":"PMC_23677909","title":"Defining the epsilon-sarcoglycan (SGCE) gene phenotypic signature in myoclonus-dystonia: a reappraisal of genetic testing criteria.","date":"2013","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/23677909","citation_count":27,"is_preprint":false},{"pmid":"18265016","id":"PMC_18265016","title":"Cortical excitability in DYT-11 positive myoclonus dystonia.","date":"2008","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/18265016","citation_count":21,"is_preprint":false},{"pmid":"25150291","id":"PMC_25150291","title":"Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25150291","citation_count":18,"is_preprint":false},{"pmid":"20372795","id":"PMC_20372795","title":"MMP-7 and SGCE as distinctive molecular factors in sporadic colorectal cancers from the mutator phenotype pathway.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20372795","citation_count":18,"is_preprint":false},{"pmid":"36204995","id":"PMC_36204995","title":"Cortical neuronal hyperexcitability and synaptic changes in SGCE mutation-positive myoclonus dystonia.","date":"2023","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36204995","citation_count":16,"is_preprint":false},{"pmid":"18651096","id":"PMC_18651096","title":"Cryptic 7q21 and 9p23 deletions in a patient with apparently balanced de novo reciprocal translocation t(7;9)(q21;p23) associated with a dystonia-plus syndrome: paternal deletion of the epsilon-sarcoglycan (SGCE) gene.","date":"2008","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18651096","citation_count":16,"is_preprint":false},{"pmid":"28155872","id":"PMC_28155872","title":"Faithful SGCE imprinting in iPSC-derived cortical neurons: an endogenous cellular model of myoclonus-dystonia.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28155872","citation_count":15,"is_preprint":false},{"pmid":"18098280","id":"PMC_18098280","title":"Large deletions account for an increasing number of mutations in SGCE.","date":"2008","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/18098280","citation_count":15,"is_preprint":false},{"pmid":"33022436","id":"PMC_33022436","title":"Delineating the motor phenotype of SGCE-myoclonus dystonia syndrome.","date":"2020","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/33022436","citation_count":14,"is_preprint":false},{"pmid":"17702041","id":"PMC_17702041","title":"Autosomal dominant myoclonus-dystonia and Tourette syndrome in a family without linkage to the SGCE gene.","date":"2007","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/17702041","citation_count":13,"is_preprint":false},{"pmid":"24716024","id":"PMC_24716024","title":"An Asian Patient with Myoclonus-Dystonia (DYT11) Responsive to Deep Brain Stimulation of the Globus Pallidus Internus.","date":"2014","source":"Case reports in neurological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24716024","citation_count":13,"is_preprint":false},{"pmid":"33808167","id":"PMC_33808167","title":"Functional and Molecular Properties of DYT-SGCE Myoclonus-Dystonia Patient-Derived Striatal Medium Spiny Neurons.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33808167","citation_count":12,"is_preprint":false},{"pmid":"32878957","id":"PMC_32878957","title":"The Landscape of Genomic Imprinting at the Porcine SGCE/PEG10 Locus from Methylome and Transcriptome of Parthenogenetic Embryos.","date":"2020","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32878957","citation_count":11,"is_preprint":false},{"pmid":"37838174","id":"PMC_37838174","title":"SGCE promotes breast cancer stemness by promoting the transcription of FGF-BP1 by Sp1.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37838174","citation_count":10,"is_preprint":false},{"pmid":"20800530","id":"PMC_20800530","title":"Large SGCE deletion contributes to Taiwanese myoclonus-dystonia syndrome.","date":"2010","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/20800530","citation_count":10,"is_preprint":false},{"pmid":"15368614","id":"PMC_15368614","title":"Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder.","date":"2004","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/15368614","citation_count":9,"is_preprint":false},{"pmid":"33200041","id":"PMC_33200041","title":"Population Prevalence of Deleterious SGCE Variants.","date":"2020","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33200041","citation_count":8,"is_preprint":false},{"pmid":"30334277","id":"PMC_30334277","title":"Delineating cerebellar mechanisms in DYT11 myoclonus-dystonia.","date":"2018","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/30334277","citation_count":8,"is_preprint":false},{"pmid":"27242657","id":"PMC_27242657","title":"Distribution and Coexistence of Myoclonus and Dystonia as Clinical Predictors of SGCE Mutation Status: A Pilot Study.","date":"2016","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27242657","citation_count":8,"is_preprint":false},{"pmid":"26278497","id":"PMC_26278497","title":"A child with myoclonus-dystonia (DYT11) misdiagnosed as atypical opsoclonus myoclonus syndrome.","date":"2015","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/26278497","citation_count":6,"is_preprint":false},{"pmid":"23140253","id":"PMC_23140253","title":"Incomplete nonsense-mediated decay facilitates detection of a multi-exonic deletion mutation in SGCE.","date":"2012","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23140253","citation_count":6,"is_preprint":false},{"pmid":"22026499","id":"PMC_22026499","title":"A novel SGCE gene mutation causing myoclonus dystonia in a family with an unusual phenotype.","date":"2011","source":"Acta paediatrica (Oslo, Norway : 1992)","url":"https://pubmed.ncbi.nlm.nih.gov/22026499","citation_count":6,"is_preprint":false},{"pmid":"19147379","id":"PMC_19147379","title":"Myoclonus in fraternal twin toddlers: a French family with a novel mutation in the SGCE gene.","date":"2009","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/19147379","citation_count":6,"is_preprint":false},{"pmid":"28690014","id":"PMC_28690014","title":"Psychiatric symptoms in myoclonus-dystonia syndrome are just concomitant features regardless of the SGCE gene mutation.","date":"2017","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/28690014","citation_count":5,"is_preprint":false},{"pmid":"29607243","id":"PMC_29607243","title":"Hereditary Myoclonus Dystonia: A Novel SGCE Variant and Phenotype Including Intellectual Disability.","date":"2018","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29607243","citation_count":4,"is_preprint":false},{"pmid":"32955639","id":"PMC_32955639","title":"A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability.","date":"2020","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/32955639","citation_count":3,"is_preprint":false},{"pmid":"31392249","id":"PMC_31392249","title":"A Novel SGCE Nonsense Variant Associated With Marked Intrafamilial Variability in a Turkish Family With Myoclonus-Dystonia.","date":"2019","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/31392249","citation_count":3,"is_preprint":false},{"pmid":"38575756","id":"PMC_38575756","title":"Pallidal deep brain stimulation for patients with myoclonus-dystonia without SGCE mutations.","date":"2024","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38575756","citation_count":2,"is_preprint":false},{"pmid":"30849405","id":"PMC_30849405","title":"Screening for SGCE mutations in Moroccan sporadic patients with Myoclonus-Dystonia syndrome.","date":"2019","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30849405","citation_count":2,"is_preprint":false},{"pmid":"35340658","id":"PMC_35340658","title":"Detection of a new deleterious SGCE gene variant in Moroccan family with inherited myoclonus-dystonia.","date":"2022","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/35340658","citation_count":2,"is_preprint":false},{"pmid":"23561547","id":"PMC_23561547","title":"A novel conserved mutation in SGCE gene in 3 unrelated patients with classical phenotype myoclonus-dystonia syndrome.","date":"2013","source":"Neurological research","url":"https://pubmed.ncbi.nlm.nih.gov/23561547","citation_count":2,"is_preprint":false},{"pmid":"25868953","id":"PMC_25868953","title":"Japanese familial case of myoclonus-dystonia syndrome with a splicing mutation in SGCE.","date":"2015","source":"Pediatrics international : official journal of the Japan Pediatric Society","url":"https://pubmed.ncbi.nlm.nih.gov/25868953","citation_count":2,"is_preprint":false},{"pmid":"29429788","id":"PMC_29429788","title":"Novel SGCE mutation in a patient with myoclonus-dystonia syndrome - Diagnostic delay of more than 40 years.","date":"2018","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/29429788","citation_count":2,"is_preprint":false},{"pmid":"32115676","id":"PMC_32115676","title":"Myoclonus-dystonia (DYT11, DYT-SGCE) - a channelopathy?","date":"2020","source":"Neurologia i neurochirurgia polska","url":"https://pubmed.ncbi.nlm.nih.gov/32115676","citation_count":1,"is_preprint":false},{"pmid":"40557327","id":"PMC_40557327","title":"Sex-specific alterations of Purkinje cell firing in Sgce knockout mice and correlations with myoclonus.","date":"2025","source":"Dystonia (Lausanne, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40557327","citation_count":1,"is_preprint":false},{"pmid":"38486676","id":"PMC_38486676","title":"Novel SGCE Mutation in a Patient With Myoclonus-Dystonia: A Case Report.","date":"2024","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38486676","citation_count":1,"is_preprint":false},{"pmid":"36161439","id":"PMC_36161439","title":"Loss-of-function mutations in SGCE found in Japanese patients with myoclonus-dystonia.","date":"2022","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36161439","citation_count":1,"is_preprint":false},{"pmid":"32102149","id":"PMC_32102149","title":"[Clinical and genetic analysis of childhood-onset myoclonus dystonia syndrome caused by SGCE variants].","date":"2020","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32102149","citation_count":1,"is_preprint":false},{"pmid":"39704115","id":"PMC_39704115","title":"Sodium Oxybate-Treated Familial Myoclonus-Dystonia Syndrome Due to Novel SGCE Variant.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/39704115","citation_count":1,"is_preprint":false},{"pmid":"34986800","id":"PMC_34986800","title":"A mixed-ethnicity myoclonus-dystonia patient with a novel SGCE nonsense mutation: a case report.","date":"2022","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34986800","citation_count":1,"is_preprint":false},{"pmid":"41331696","id":"PMC_41331696","title":"From SGCE gene to symptoms: decoding myoclonus-dystonia.","date":"2025","source":"Acta neurologica Belgica","url":"https://pubmed.ncbi.nlm.nih.gov/41331696","citation_count":0,"is_preprint":false},{"pmid":"38594908","id":"PMC_38594908","title":"The landscape of allelic expression and DNA methylation at the bovine SGCE/PEG10 locus.","date":"2024","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38594908","citation_count":0,"is_preprint":false},{"pmid":"37846277","id":"PMC_37846277","title":"Two-Generation Epsilon-Sarcoglycan Gene (SGCE) Mutation-Associated Myoclonus-Dystonia (DYT-SGCE) Misdiagnosed as Tourette's Syndrome: A Case Series.","date":"2023","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/37846277","citation_count":0,"is_preprint":false},{"pmid":"40711998","id":"PMC_40711998","title":"Transcriptomic disruption and hypoactivity in DYT-SGCE medial ganglionic eminence-patterned inhibitory neurons.","date":"2026","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40711998","citation_count":0,"is_preprint":false},{"pmid":"40717718","id":"PMC_40717718","title":"SGCE Myoclonus Dystonia: A Case Report.","date":"2025","source":"Ethiopian journal of health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40717718","citation_count":0,"is_preprint":false},{"pmid":"35995778","id":"PMC_35995778","title":"A Japanese family with dystonia due to a pathogenic variant in SGCE.","date":"2022","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/35995778","citation_count":0,"is_preprint":false},{"pmid":"35263928","id":"PMC_35263928","title":"A Case Report of Siblings with Dystonia: A Potential Link Between DYT11 Mutation and Platelet Dysfunction.","date":"2022","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/35263928","citation_count":0,"is_preprint":false},{"pmid":"31413899","id":"PMC_31413899","title":"Gait Impairment in Myoclonus-Dystonia (DYT-SGCE).","date":"2019","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31413899","citation_count":0,"is_preprint":false},{"pmid":"41982418","id":"PMC_41982418","title":"Beyond SGCE: expanding the clinical and molecular spectrum of KCTD17- and KCNN2-related myoclonus-dystonia.","date":"2026","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/41982418","citation_count":0,"is_preprint":false},{"pmid":"42063207","id":"PMC_42063207","title":"Distinct Brain Drivers and Shared Cerebello-Cortical Input in ADCY5 and SGCE Hyperkinetic Movements.","date":"2026","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/42063207","citation_count":0,"is_preprint":false},{"pmid":"42164952","id":"PMC_42164952","title":"An 18-fluorodeoxyglucose-PET study in SGCE positive and negative myoclonus-dystonia.","date":"2026","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/42164952","citation_count":0,"is_preprint":false},{"pmid":"36274329","id":"PMC_36274329","title":"Clinical features and genetic analysis of SGCE myoclonus-dystonia: A case report.","date":"2022","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/36274329","citation_count":0,"is_preprint":false},{"pmid":"41613668","id":"PMC_41613668","title":"Infantile Epsilon-Sarcoglycan (SGCE) Myoclonus-Dystonia: Diagnostic Pitfalls and Poor Response to Pharmacologic Treatment.","date":"2025","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/41613668","citation_count":0,"is_preprint":false},{"pmid":"41780719","id":"PMC_41780719","title":"Intrafamilial variability of myoclonic dystonia in a large French family carrying a novel SGCE variant.","date":"2026","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41780719","citation_count":0,"is_preprint":false},{"pmid":"41747888","id":"PMC_41747888","title":"Intrafamilial variability of myoclonic dystonia in a large French family carrying a novel SGCE variant.","date":"2026","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41747888","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.12.19.629430","title":"Transcriptomic disruption and functional hypoactivity in DYT-  <i>SGCE</i>  MGE-patterned inhibitory neurons","date":"2024-12-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.19.629430","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.13.648593","title":"Developmental, neuroanatomical and cellular expression of genes causing dystonia","date":"2025-04-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.13.648593","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.17.24317299","title":"Associations between DNA methylation and cognitive function in early-stage hormone receptor-positive breast cancer patients","date":"2024-11-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.17.24317299","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.02.24316741","title":"Genetic Diversity and Expanded Phenotypes in Dystonia: Insights from Large-Scale Exome Sequencing","date":"2024-12-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.02.24316741","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38453,"output_tokens":4438,"usd":0.090965,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12625,"output_tokens":4354,"usd":0.085987,"stage2_stop_reason":"end_turn"},"total_usd":0.176952,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"The maternal allele of SGCE is methylated while the paternal allele is unmethylated in peripheral blood leukocytes and brain tissue, establishing maternal imprinting of SGCE. Expression from the maternal allele is silenced (weak RT-PCR signal in matUPD7 vs. strong signal in patUPD7 cell lines), confirming that only the paternal allele is expressed.\",\n      \"method\": \"Bisulfite genomic sequencing of CpG dinucleotides in the promoter/first exon; RT-PCR in uniparental disomy 7 (UPD7) lymphoblastoid cell lines\",\n      \"journal\": \"European journal of human genetics : EJHG\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct methylation assay with functional expression confirmation, replicated across blood and brain tissue and in UPD7 cell lines\",\n      \"pmids\": [\"12634861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MDS-associated SGCE missense mutations (H36P, H36R, L172R) cause intracellular retention of ε-sarcoglycan and prevent trafficking to the plasma membrane. The mutant proteins become polyubiquitinated and are rapidly degraded by the proteasome. TorsinA (mutated in DYT1 dystonia) binds to and promotes degradation of misfolded ε-sarcoglycan mutants when co-expressed.\",\n      \"method\": \"Biosynthesis and trafficking assays in cultured cells; cell-surface expression analysis; co-immunoprecipitation of torsinA with ε-sarcoglycan mutants; proteasome inhibitor experiments; polyubiquitination assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (trafficking assay, co-IP, ubiquitination assay, proteasome inhibition) in a single focused study\",\n      \"pmids\": [\"17200151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Loss of ε-sarcoglycan (Sgce KO mice) results in significantly decreased striatal dopamine D2 receptor (D2R) protein levels without altering dopamine transporter (DAT) or D1 receptor levels, and leads to increased dopamine release after amphetamine injection, suggesting ε-SG plays a role in regulating D2R expression and striatal dopamine homeostasis.\",\n      \"method\": \"Western blot for D2R, DAT, D1R in striatum of Sgce KO mice; in vivo microdialysis measuring dopamine release after amphetamine injection\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (Western blot + microdialysis) in single-lab KO mouse study\",\n      \"pmids\": [\"22438980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ε-Sarcoglycan is required in cerebellar Purkinje cells for motor learning; Purkinje cell-specific Sgce conditional knockout (Sgce pKO) mice show motor learning deficits. Additionally, Sgce KO mice show abnormal nuclear envelope morphology in cerebellar Purkinje cells detected by transmission electron microscopy.\",\n      \"method\": \"Cerebellar Purkinje cell-specific conditional Sgce knockout mice; beam-walking behavioral tests; transmission electron microscopy of nuclear envelope\",\n      \"journal\": \"Behavioural brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined behavioral phenotype plus ultrastructural analysis, single lab\",\n      \"pmids\": [\"22040906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mice carrying mutations in both Dyt1 (torsinA) and Sgce (ε-sarcoglycan) show earlier onset of motor deficits compared to single mutants, suggesting genetic interaction between these two dystonia genes. Western blot analysis suggested that functional deficits of torsinA and ε-sarcoglycan may independently cause motor deficits rather than acting in a shared pathway.\",\n      \"method\": \"Double mutant mouse generation; beam-walking test; Western blot with novel monoclonal anti-mouse ε-sarcoglycan antibody developed in Sgce KO mice\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis experiment in double-mutant mice with behavioral readout, single lab\",\n      \"pmids\": [\"20627944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of Sgce in the striatum specifically impairs long-term depression (LTD) at corticostriatal glutamatergic synapses in medium spiny neurons, without affecting intrinsic electrophysiological properties or basal synaptic transmission. Pharmacological inhibition of adenosine A2A receptors (A2AR) restores LTD in Sgce mutant mice.\",\n      \"method\": \"RNAseq of Sgce mutant striatum; electrophysiological recordings (LTD induction by high-frequency stimulation) in striatal medium spiny neurons and cholinergic interneurons; pharmacological A2AR inhibition\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro electrophysiology with pharmacological rescue, combined with transcriptomic analysis, multiple orthogonal methods\",\n      \"pmids\": [\"28823931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Acute knockdown of Sgce specifically in the cerebellum (but not the basal ganglia) of adult mice produces dystonia and repetitive myoclonic-like jerking movements that improve after ethanol administration, demonstrating that cerebellar loss of ε-sarcoglycan is sufficient to cause the core DYT11 motor symptoms and that aberrant cerebellar activity underlies the motor phenotype.\",\n      \"method\": \"shRNA-mediated acute knockdown of Sgce in adult mouse cerebellum or basal ganglia; behavioral assessment of dystonia and myoclonus; ethanol administration\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — region-specific knockdown with clear positive vs. negative controls (cerebellum vs. basal ganglia), ethanol-reversibility confirms specificity\",\n      \"pmids\": [\"31868164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Immunoaffinity purification followed by mass spectrometry of Sgce-mutant mouse brain showed significant reductions of ε-SG and other interacting sarcoglycans, indicating that ε-sarcoglycan forms complexes with other sarcoglycan family members in brain. The brain-specific Sgce isoform incorporating exon 11b is most highly expressed in cerebellum (Purkinje cells and dentate nucleus neurons).\",\n      \"method\": \"Immunoaffinity purification with pan- or brain-specific ε-SG antibodies followed by mass spectrometry; isoform expression analysis; gene-trap mouse model\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry-based interactome in brain tissue, single lab, supported by expression analysis\",\n      \"pmids\": [\"27890709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"iPSC-derived cortical neurons from myoclonus-dystonia patients with SGCE mutations (W100G and R102X) maintain faithful maternal imprinting of SGCE (differential methylation is tissue-independent). The brain-specific SGCE mRNA isoform and ε-sarcoglycan protein are detected in iPSC-derived neurons (but not in fibroblasts), and neuronal protein levels are reduced in both mutant lines.\",\n      \"method\": \"Methylation-specific PCR; cDNA analysis; RT-PCR for brain-specific isoform; Western blot for ε-sarcoglycan protein; iPSC reprogramming and neuronal differentiation\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (methylation, expression, protein) in patient-derived iPSC-neurons, single lab\",\n      \"pmids\": [\"28155872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SGCE functions as a sponge molecule that prevents interaction between EGFR and its E3 ubiquitin ligase c-Cbl, thereby inhibiting EGFR lysosomal degradation and stabilizing EGFR protein in breast cancer stem cells. SGCE depletion promotes sensitivity to EGFR tyrosine kinase inhibitors.\",\n      \"method\": \"Co-immunoprecipitation of SGCE with EGFR and c-Cbl; SGCE knockdown with assessment of EGFR protein stability; in vitro and in vivo functional assays; single-cell resolution gene expression analysis\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional consequence of knockdown, single lab, in cancer cell context distinct from neurological function\",\n      \"pmids\": [\"32714745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SGCE mutations cause cortical neuronal hyperexcitability: iPSC-derived cortical glutamatergic neurons carrying SGCE mutations show increased network activity, greater propensity for action potential generation, longer axon initial segments, and more complex dendritic morphology compared to isogenic wild-type controls. SGCE mutations are associated with higher presynaptic neurexin-1 and lower postsynaptic neuroligin-4 levels, indicating disruption of synaptic adhesion molecule expression.\",\n      \"method\": \"CRISPR/Cas9-edited human embryonic stem cell line with SGCE compound heterozygous mutation; patient-derived iPSC lines with isogenic wild-type controls; Ca2+ imaging; microelectrode array; single-cell patch clamp; bulk RNA sequencing; dendritic morphology analysis; Western blot for synaptic proteins and receptor subunits\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (electrophysiology, Ca2+ imaging, MEA, morphology, proteomics) with isogenic controls in two independent cell models\",\n      \"pmids\": [\"36204995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"iPSC-derived striatal medium spiny neurons (MSNs) from SGCE mutation carriers show elevated basal intracellular Ca2+ content, lower frequency of spontaneous Ca2+ signals, increased Ca2+ amplitudes upon glycine and acetylcholine application, reduced GABAergic synaptic density, and elevated amplitudes of miniature postsynaptic currents and action potentials, indicating that SGCE loss causes specific alterations in MSN calcium signaling and synaptic function.\",\n      \"method\": \"iPSC-derived striatal MSN differentiation; calcium imaging; whole-cell patch-clamp recordings; immunofluorescence for GABAergic synaptic density; pharmacological blocking with verapamil\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple electrophysiological and imaging methods in patient-derived iPSC model, single lab\",\n      \"pmids\": [\"33808167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SGCE interacts with the transcription factor Sp1 and translocates into the nucleus, leading to increased transcription of the secreted oncoprotein FGF-BP1, which in turn activates FGF-FGFR signaling to promote cancer cell stemness.\",\n      \"method\": \"Co-immunoprecipitation of SGCE with Sp1; nuclear translocation assay; FGF-BP1 promoter transcription assays; SGCE knockdown with FGF-BP1 expression measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and nuclear localization with functional transcriptional readout, single lab, cancer cell context\",\n      \"pmids\": [\"37838174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Two SGCE missense mutations (c.662G>T/p.Gly221Val and c.1345A>G/p.Met449Val) and a 15 bp deletion (c.168_182del/p.Phe58_Leu62del) cause significant reduction in cell membrane expression of ε-sarcoglycan. Minigene assays demonstrated that c.662G>T and c.825+1G>C mutations cause complete skipping of exon 5 and exon 6, respectively.\",\n      \"method\": \"HiBiT bioluminescence assay for cell membrane expression; minigene splicing assay\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional cell membrane trafficking assay and minigene splicing assay, two orthogonal methods, single lab\",\n      \"pmids\": [\"36161439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Purkinje cells from Sgce KO mice show altered spontaneous firing and intrinsic excitability changes compared to wild-type mice, without changes in intrinsic membrane properties. Female Sgce KO mice have more profound alterations in Purkinje cell firing than males, correlating with earlier symptom onset and more pronounced myoclonus in female mice.\",\n      \"method\": \"Acute cerebellar slice electrophysiological recordings in Sgce KO mice; comparison of spontaneous firing rates and intrinsic excitability between sexes\",\n      \"journal\": \"Dystonia (Lausanne, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ex vivo electrophysiology in KO mice, single lab, single method but clear functional readout\",\n      \"pmids\": [\"40557327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SGCE mutation-carrying MGE-derived inhibitory GABAergic neurons show transcriptomic dysregulation in genes related to axonal organization, synaptic signalling, and action potential generation; reduced neurite outgrowth; lower calcium responses to GABA; decreased neuronal excitability and network activity; and fewer spontaneous postsynaptic currents compared to isogenic wild-type controls. This hypoactive inhibitory phenotype contrasts with the hyperexcitable phenotype previously observed in SGCE-mutant cortical glutamatergic neurons, indicating disruption of excitatory-inhibitory balance.\",\n      \"method\": \"Patient-derived iPSC and CRISPR/Cas9-edited ESC lines; single-cell RNA sequencing; Ca2+ imaging; multi-electrode array; whole-cell patch-clamp; dendritic morphology analysis\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (scRNA-seq, electrophysiology, Ca2+ imaging, MEA, morphology) with isogenic controls, replicates and extends prior cortical neuron findings\",\n      \"pmids\": [\"40711998\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ε-Sarcoglycan (SGCE) is a maternally imprinted, paternally expressed transmembrane protein whose loss-of-function causes myoclonus-dystonia (DYT11) through disruption of cerebellar Purkinje cell firing and corticostriatal long-term depression, with disease-associated missense mutations causing intracellular retention, polyubiquitination and proteasomal degradation of the misfolded protein; torsinA promotes degradation of these mutants. In cortical glutamatergic neurons, SGCE loss results in hyperexcitability and altered synaptic adhesion molecule expression (higher neurexin-1, lower neuroligin-4), while in striatal GABAergic neurons it causes hypoactivity and reduced synaptic density, collectively disrupting excitatory-inhibitory balance. ε-Sarcoglycan also regulates striatal dopamine D2 receptor expression and dopamine release, and in cancer cells acts as a scaffold that prevents EGFR-c-Cbl interaction to stabilize EGFR and, separately, interacts with Sp1 to promote nuclear transcription of FGF-BP1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ε-Sarcoglycan (SGCE) is a maternally imprinted, paternally expressed transmembrane sarcoglycan whose loss disrupts neuronal excitability and synaptic function, and whose mutation causes myoclonus-dystonia (DYT11) [#0, #6]. The maternal allele is silenced by promoter methylation in blood and brain, so disease arises from paternally inherited loss-of-function alleles [#0], an imprinting pattern faithfully maintained in patient iPSC-derived neurons that express a brain-specific exon-11b isoform most abundant in cerebellum [#7, #8]. Disease-associated missense mutations cause intracellular retention, block trafficking to the plasma membrane, and trigger polyubiquitination and proteasomal degradation of the misfolded protein, with torsinA (the DYT1 dystonia protein) binding and promoting degradation of these mutants; other mutations reduce surface expression through exon skipping [#1, #13]. Functionally, ε-sarcoglycan acts within the cerebellum where its acute loss is sufficient to produce ethanol-responsive dystonia and myoclonus, and where Purkinje cell firing and intrinsic excitability are altered in a sex-dependent manner [#6, #14]. In the striatum, loss selectively impairs corticostriatal long-term depression in a manner rescuable by adenosine A2A receptor blockade, and reduces dopamine D2 receptor levels while increasing amphetamine-evoked dopamine release [#5, #2]. Across human neuronal models, SGCE loss disrupts excitatory-inhibitory balance—producing hyperexcitable cortical glutamatergic neurons with altered synaptic adhesion molecules (higher neurexin-1, lower neuroligin-4) but hypoactive GABAergic and striatal neurons with reduced synaptic density [#10, #11, #15]. In cancer cells SGCE has separable roles, acting as a scaffold that blocks EGFR–c-Cbl interaction to stabilize EGFR and interacting with Sp1 to drive nuclear transcription of FGF-BP1 [#9, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the genetic basis for parent-of-origin inheritance in DYT11 by showing SGCE is maternally imprinted, explaining why only paternally inherited mutations cause disease.\",\n      \"evidence\": \"Bisulfite sequencing and RT-PCR in UPD7 lymphoblastoid lines across blood and brain\",\n      \"pmids\": [\"12634861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the imprinting control mechanism or trans-acting factors\", \"Does not link imprinting to a specific cellular function of the protein\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the molecular consequence of disease missense mutations—misfolding, ER retention, and proteasomal degradation—and connected SGCE to torsinA, a second dystonia protein.\",\n      \"evidence\": \"Trafficking, co-IP, ubiquitination, and proteasome inhibition assays in cultured cells\",\n      \"pmids\": [\"17200151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish the normal surface function of wild-type ε-sarcoglycan\", \"torsinA interaction tested only with mutants, not normal turnover\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked ε-sarcoglycan loss to striatal dopamine homeostasis, implicating D2 receptor regulation and dopamine release as candidate disease mechanisms.\",\n      \"evidence\": \"Western blot and in vivo microdialysis in Sgce KO mice\",\n      \"pmids\": [\"22438980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ε-SG regulates D2R levels unknown\", \"Does not connect dopamine changes to motor phenotype\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Tested whether the two dystonia genes act in a shared pathway, finding a genetic interaction but evidence for independent contributions to motor deficits.\",\n      \"evidence\": \"Dyt1/Sgce double-mutant mice with beam-walking and Western blot\",\n      \"pmids\": [\"20627944\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not resolve whether the interaction is direct or convergent\", \"Mechanism of earlier onset not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Localized a motor-learning requirement for ε-sarcoglycan to cerebellar Purkinje cells and revealed nuclear envelope abnormalities there.\",\n      \"evidence\": \"Purkinje cell-specific conditional Sgce KO, beam-walking, and TEM\",\n      \"pmids\": [\"22040906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional significance of nuclear envelope defect unclear\", \"Does not link Purkinje phenotype to myoclonus or dystonia\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified a defined synaptic plasticity defect—impaired corticostriatal LTD—with a pharmacological rescue point at the adenosine A2A receptor.\",\n      \"evidence\": \"Striatal slice electrophysiology with A2AR inhibition plus RNAseq in Sgce mutant mice\",\n      \"pmids\": [\"28823931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between ε-SG and A2AR signaling unknown\", \"LTD defect not yet tied to behavioral output\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that ε-sarcoglycan forms complexes with other sarcoglycans in brain and identified a cerebellum-enriched brain-specific isoform.\",\n      \"evidence\": \"Immunoaffinity purification–mass spectrometry and isoform analysis in mouse brain\",\n      \"pmids\": [\"27890709\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of the brain sarcoglycan complex not defined\", \"Identity of all complex members and stoichiometry incomplete\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Confirmed in human patient iPSC-neurons that SGCE imprinting is tissue-independent and that mutant protein levels are reduced, validating the model in human cells.\",\n      \"evidence\": \"Methylation PCR, isoform RT-PCR, and Western blot in patient iPSC-derived neurons\",\n      \"pmids\": [\"28155872\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not assess neuronal physiology or function\", \"Two mutation lines only\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed that cerebellar loss of ε-sarcoglycan alone is sufficient to produce the core, ethanol-responsive DYT11 motor phenotype, establishing the cerebellum as a primary disease locus.\",\n      \"evidence\": \"Region-specific shRNA knockdown in adult mouse cerebellum versus basal ganglia with behavioral and ethanol testing\",\n      \"pmids\": [\"31868164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular circuit producing aberrant activity not fully mapped\", \"Mechanism of ethanol responsiveness unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Characterized striatal MSN dysfunction in human cells, revealing altered calcium signaling and reduced GABAergic synaptic density upon SGCE loss.\",\n      \"evidence\": \"Calcium imaging, patch-clamp, and immunofluorescence in patient iPSC-derived MSNs\",\n      \"pmids\": [\"33808167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between Ca2+ alterations and synaptic loss unclear\", \"Single-lab patient lines\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended the trafficking-defect model to additional mutation classes, showing both missense and splice mutations reduce surface ε-sarcoglycan.\",\n      \"evidence\": \"HiBiT membrane-expression and minigene splicing assays\",\n      \"pmids\": [\"36161439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not assess downstream neuronal consequences\", \"Splicing outcomes inferred from minigene, not patient tissue\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated that SGCE-mutant human cortical glutamatergic neurons are hyperexcitable with altered synaptic adhesion molecule expression, defining a cell-autonomous excitatory phenotype.\",\n      \"evidence\": \"Ca2+ imaging, MEA, patch-clamp, RNAseq, and morphology in isogenic-controlled iPSC/ESC cortical neurons\",\n      \"pmids\": [\"36204995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking ε-SG loss to neurexin-1/neuroligin-4 changes unknown\", \"Does not address inhibitory neuron behavior\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a nuclear, transcriptional oncogenic role in which SGCE partners with Sp1 to drive FGF-BP1 expression and cancer stemness.\",\n      \"evidence\": \"Co-IP with Sp1, nuclear translocation, and promoter transcription assays in cancer cells\",\n      \"pmids\": [\"37838174\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How a transmembrane protein reaches the nucleus is unexplained\", \"Relationship to neuronal function unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed Purkinje cell firing and intrinsic excitability are altered in Sgce KO mice with a sex difference that correlates with disease severity.\",\n      \"evidence\": \"Ex vivo cerebellar slice electrophysiology comparing sexes in Sgce KO mice\",\n      \"pmids\": [\"40557327\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of sex difference not defined\", \"Single physiological readout\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Completed the excitatory-inhibitory picture by showing SGCE-mutant inhibitory GABAergic neurons are hypoactive, contrasting with hyperexcitable glutamatergic neurons.\",\n      \"evidence\": \"scRNA-seq, Ca2+ imaging, MEA, patch-clamp, and morphology in isogenic-controlled iPSC/ESC GABAergic neurons\",\n      \"pmids\": [\"40711998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism producing opposite phenotypes across neuron types unknown\", \"Network-level consequence of imbalance not directly measured\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The normal biochemical function of plasma-membrane ε-sarcoglycan and how its loss mechanistically produces opposite excitability changes in distinct neuron classes remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No defined molecular activity for wild-type membrane ε-sarcoglycan\", \"Mechanism connecting sarcoglycan complex to neuronal excitability unknown\", \"Reconciliation of neuronal versus cancer-nuclear roles unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 6, 10, 15]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 13]}\n    ],\n    \"complexes\": [\"sarcoglycan complex\"],\n    \"partners\": [\"TOR1A\", \"EGFR\", \"CBL\", \"SP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}